Damiano Vincenzo, Melisi Davide, Bianco Cataldo, Raben David, Caputo Rosa, Fontanini Gabriella, Bianco Roberto, Ryan Anderson, Bianco A Raffaele, De Placido Sabino, Ciardiello Fortunato, Tortora Giampaolo
Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università di Napoli Federico II, Italy.
Clin Cancer Res. 2005 Aug 1;11(15):5639-44. doi: 10.1158/1078-0432.CCR-05-0174.
Glioblastoma multiforme is an aggressive disease in which vascular endothelial growth factor (VEGF) and the EGF receptor (EGFR) are implicated in tumor growth, relapse, and resistance to radiotherapy and chemotherapy. The VEGF receptors VEGFR-1 (flt-1) and VEGFR-2 (KDR), typically present on endothelial cells, have also been identified in human glioblastoma tissues and cell lines. In addition, EGFR is dysregulated in the majority of human glioblastomas and EGFR overexpression correlates with shorter survival. We have investigated the antitumor and antiangiogenic effect of ZD6474, an inhibitor of both VEGFR and EGFR signaling as a single agent and in combination with ionizing radiation.
We have used ZD6474 and/or ionizing radiation in human glioblastoma cell lines D54 and U251 in vitro and in nude mice bearing established xenografts. The effects of treatment on tumor blood vessels and protein expression were evaluated by Western blot and immunohistochemistry.
As single agents, ionizing radiation and ZD6474 caused a dose-dependent inhibition of soft agar growth in D54 and U251 cell lines, whereas a cooperative effect was obtained in combination. Treatment of mice bearing D54 xenografts with either ZD6474 or radiotherapy alone caused tumor growth inhibition that was reversible upon treatment cessation. A cooperative and long-lasting inhibition of tumor growth was obtained with ZD6474 in combination with concomitant radiotherapy. The antiproliferative effect was accompanied by inhibition of VEGF protein expression and inhibition of angiogenesis as measured by vessel counting.
This study shows the antitumor activity of ZD6474 in combination with ionizing radiation in glioblastoma both in vitro and in vivo, and provides a scientific rationale to evaluate ZD6474 alone or in combination with radiotherapy in patients affected by this disease.
多形性胶质母细胞瘤是一种侵袭性疾病,其中血管内皮生长因子(VEGF)和表皮生长因子受体(EGFR)与肿瘤生长、复发以及对放疗和化疗的耐药性有关。VEGF受体VEGFR-1(flt-1)和VEGFR-2(KDR)通常存在于内皮细胞上,在人胶质母细胞瘤组织和细胞系中也已被鉴定出来。此外,EGFR在大多数人胶质母细胞瘤中表达失调,EGFR过表达与较短的生存期相关。我们研究了ZD6474(一种VEGFR和EGFR信号通路的抑制剂)作为单一药物以及与电离辐射联合使用时的抗肿瘤和抗血管生成作用。
我们在人胶质母细胞瘤细胞系D54和U251中以及在携带已建立异种移植瘤的裸鼠体内使用了ZD6474和/或电离辐射。通过蛋白质印迹法和免疫组织化学评估治疗对肿瘤血管和蛋白质表达的影响。
作为单一药物,电离辐射和ZD6474在D54和U251细胞系中引起软琼脂生长的剂量依赖性抑制,而联合使用时获得协同效应。单独用ZD6474或放疗治疗携带D54异种移植瘤的小鼠会导致肿瘤生长受到抑制,停止治疗后这种抑制是可逆的。ZD6474与同步放疗联合使用可获得协同且持久的肿瘤生长抑制。抗增殖作用伴随着VEGF蛋白表达的抑制以及通过血管计数测量的血管生成抑制。
本研究显示了ZD6474与电离辐射联合在体外和体内对胶质母细胞瘤的抗肿瘤活性,并为评估ZD6474单独或与放疗联合用于受该疾病影响的患者提供了科学依据。